Trilliome

Trilliome is developing a proprietary AI and human gut model platform capable of identifying molecular combinations that reprogram the microbiome — boosting keystone bacterial species and restoring functions linked to brain and immune health.

Trilliome has raised €50k across 1 funding round from 1 investor, most recently a round in Oct 2025. Based in Zurich, Switzerland; active in Healthtech. Data as of 28 Oct 2026.